Background
Vitamin D insufficiency has been increasingly recognized as a common health problem worldwide. Measures to augment vitamin D levels include increased sun exposure, higher consumption of vitamin D-rich foods, and taking vitamin D supplements. In order to achieve a 25-hydroxyvitamin D level [25(OH)D; a marker of vitamin D status] higher than the current recommended threshold of 50-75 nmol/L, higher doses of vitamin D than previously suggested are required in Caucasians [1, 2] .
However, it is unclear if the suggestion holds across ethnic groups, particularly in populations with lower body fat as compared to Caucasians. Moreover, it has never been investigated in Asians if vitamin D 2 or D 3 supplementation would have a different effect on circulating vitamin D.
Vitamin D and its metabolites circulate in the plasma, bound to vitamin D binding protein (DBP) [3] . Genetic variations in the DBP gene have consistently been found to be associated with 25(OH)D levels [4] [5] [6] [7] . However, it is currently unclear how the DBP genetic variation would affect the increase in 25(OH)D levels after taking vitamin D supplements.
In the present study, we investigated the changes of total 25(OH)D, 25(OH)D 3 
Methods

Subjects
A total of 41 subjects (34 females/7 males) aged 15-70 years were enrolled in an unblinded randomized control trial that began in August 2008. All subjects were healthy and did not have any underlying diseases. Subjects were excluded if they were taking vitamin D ≥400 IU/d before being included in the study. After inclusion, subjects were excluded from the final analysis if they were intolerant to the supplement or were lost to follow-up. Subjects were then randomly assigned into two groups, using a computer-generated randomized code, to receive 400 IU/ day of either vitamin D 2 or vitamin D 3 for 3 months. Two subjects (both of them were females) in the vitamin D 2 group were excluded from the study after enrollment; one subject had gastrointestinal side effects from the calcium supplement, and the second was lost to follow-up. Final analysis was based on data from 39 subjects (32 females/7 males): 20 and 19 subjects in the vitamin D 3 and D 2 groups, respectively. All subjects were supplemented during the rainy or winter season and we did not allow taking any additional vitamin supplement. The treatment period was only 3 months and all subjects stayed in the same environment. In addition, there is less natural vitamin D containing food and vitamin D fortified food in Thailand. Therefore we did not assess the duration of sun exposure and the amount of daily vitamin D intake.
All study participants arrived at the research unit at 0800 h after at least a 12 h overnight fast. Baseline characteristics -which included age, all medications currently in use, waist circumference (WC) and body mass index (BMI) -were recorded. Blood was collected at baseline. Subjects received either vitamin D 3 
SNP genotyping
DNA was extracted from a 200 μL serum sample using a QIAamp W DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Individual genotyping of rs4588 in the DBP gene was performed using real-time PCR (TaqMan W MGB probes): 20 ng of DNA was added into the PCR reaction, consisting of TaqMan Universal Master Mix (1×) and TaqMan MGB probes for intronic C/A SNP rs4588 (1×) in a total volume of 20 μL. The real-time PCR reaction protocol was 10 min at 95°C, 40 cycles of 15 s at 92°C, and 1 min at 60°C using a 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Data were expressed as mean ± SEM unless stated otherwise. We performed non-parametric test to compare the difference between parameters. We used the 
Results
Thirty-nine subjects (82.05% female) with a mean age of 36.2 ± 1.3 were included in the final analysis. All baseline characteristics of subjects in both vitamin D 3 and vitamin D 2 groups were similar (Table 1) Table 2 shows the genotype distribution of the DBP rs4588 SNP. The genotype distributions of subjects given vitamin D 3 or vitamin D 2 supplements were not significantly different. Subjects in each vitamin D supplementation group were then divided into two subgroups based on the presence of the A (minor) allele: those homozygous for the C allele (group 1), and the rest (CA or AA: group 2). When we compared baseline 25(OH)D and 25(OH)D 3 levels in subjects between group 1 (n = 22) and group 2 (n = 17), there was no difference in either baseline 25(OH)D (52.9 ± 4 vs. 52.1 ± 3 nmol/L, p = 0.5) or baseline 25(OH)D 3 levels (51.4 ± 4.1 vs. 50.6 ± 3 nmol/L, p = 0.6). We further classified subjects into 4 groups according to DBP genotype and type of vitamin D supplement ( some differences were found in gender, baseline 25(OH) D 3 and total 25(OH)D between the genotypes among subjects in the vitamin D 3 group (Table 3) . When comparing changes in vitamin D metabolites at 3 months with baseline values (Table 4) , it was found that subjects in group 2 (CA or AA alleles) had significantly less increase in 25(OH)D 3 levels after taking vitamin D 3 .
Likewise, the increment in total 25(OH)D was lower. On the other hand, no difference in the increments of 25(OH)D 3 , 25(OH)D 2 or total 25(OH)D was detected between the two genotype groups when the supplement was vitamin D 2 . There was no difference in changes in serum intact PTH between two DBP genotype subgroups after 3 months of vitamin D supplementation (Table 4) .
Discussion
In the present study, 400 IU/day of vitamin D 3 [15] , enzymatic degradation of vitamin D metabolites [8] , and dietary composition [16] , as well as fat malabsorption [17] . In the present study, vitamin D 2 or vitamin D 3 supplementation resulted in varying increases in 25(OH)D. No association with adiposity as assessed by BMI, however, was demonstrated. Since the number of study subjects was small, the lack of power to detect association could possibly be responsible. Dietary composition and enzymatic degradation of vitamin D metabolites were not assessed in the present study.
The present study demonstrated that DBP genetic variation is another factor which can influence the responsiveness to vitamin D supplementation. The major function of DBP is the binding, solubilization and transport of vitamin D and its metabolites [18] . A previous study found that both serum 25(OH)D 3 and 1, 25(OH) 2 D 3 concentrations were significantly lower in mice lacking DBP, compared to wild-type mice [19] . In another recent study, Lauridsen et al. showed that DBP phenotype determines the median plasma concentration of 25(OH)D 3 and 1, 25(OH) 2 D 3 [5] . With regard to genetic variation, single nucleotide polymorphisms in the DBP gene have been demonstrated to be related to 25(OH)D levels in Caucasians and Africans [4, 6] . A 3 supplementation, and thus possibly affect the total 25(OH)D levels at the end of the study. The change in 25(OH)D at the end of the study may also be influenced by lifestyle factors influencing the degree of sun exposure during the course of the study. This potential confounding effect cannot be assessed since there was not a non-supplemented group in our study. It would be important to know if both the vitamin D 2 and vitamin D 3 supplements had the same amount of vitamin D. However, vitamin D contents of both preparations were not measured. However, total 25(OH)D levels of subjects in both groups were similar at 3 months, suggesting that the variability in vitamin D content between vitamin D 2 and vitamin D 3 preparations, if any existed, was likely to be small. The other limitation is that multivitamin tablets containing vitamin D were used (in the vitamin D 2 group), and it is unknown if other constituents of the multivitamin would affect vitamin D absorption or metabolism. It has been demonstrated that statins, atorvastatin and rosuvastatin in particular, can influence the circulating levels of 25(OH)D [21] [22] [23] . To our knowledge, no interference from common vitamins and minerals with vitamin D metabolism has been reported.
Conclusion
Daily supplementation with vitamin D 2 tended to result in lower total 25(OH)D levels than supplementation with vitamin D 3 due to a concurrent decrease in 25(OH)D 3 levels in the former case. Genetic variation in vitamin D binding protein (rs4588 SNP) influences responsiveness to vitamin D 3 but not vitamin D 2 .
